A A van de Loosdrecht

Publications (2)10.66 Total impact

• Article: Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

  L H van der Helm, N J G M Veeger, M van Marwijk Kooy, A Beeker, O de Weerdt, M de Groot, C Alhan, M Hoogendoorn, L Laterveer, A A van de Loosdrecht, J Koedam, E Vellenga, G Huls
  [show abstract] [hide abstract]
  ABSTRACT: The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score ≥2, and white blood cell count ≥15×10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts.
  Leukemia research 04/2013; · 2.36 Impact Factor
• Article: Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.

  S Daenen, B van der Holt, A W Dekker, R Willemze, A W Rijneveld, B J Biemond, P Muus, A A van de Loosdrecht, H C Schouten, M van Marwijk Kooy, D A Breems, H Demuynck, J Maertens, P W Wijermans, S Wittebol, E W de Klerk, J J Cornelissen
  Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 02/2012; 26(7):1726-9. · 8.30 Impact Factor